| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A mixed-methods study characterizing experiences of medical oncologists’ use of gonadotropin-releasing hormone agonists for treatment of breast cancer
|
Lee, Kimberley T.
|
|
|
212 |
3 |
p. 449-455
|
artikel
|
| 2 |
Breast imaging recommendations for young females (age < 40 years) with ≥ 20% lifetime breast cancer risk: practice patterns at a specialized clinic
|
Wehbe, Alexandra
|
|
|
212 |
3 |
p. 467-474
|
artikel
|
| 3 |
Continuous glucose monitoring to characterize hyperglycemia during chemotherapy for early stage breast cancer
|
Ulene, Sophie R.
|
|
|
212 |
3 |
p. 511-519
|
artikel
|
| 4 |
Correction: Evaluating the impact of histological vs. nuclear grading on CPS + EG Score for HR + /HER2-early breast cancer
|
Braun, M.
|
|
|
212 |
3 |
p. 579
|
artikel
|
| 5 |
Effect of pretreatment lab abnormalities on the time-to-treatment discontinuation and overall survival of metastatic breast cancer patients receiving CDK 4/6i, PI3Ki, and/or mTORi
|
Franks, Jeffrey
|
|
|
212 |
3 |
p. 545-553
|
artikel
|
| 6 |
Efficacy and safety of entinostat plus exemestane in hormone receptor-positive breast cancer: a systematic review meta-analysis of randomized controlled trials
|
Mustafa, Nour Maher
|
|
|
212 |
3 |
p. 417-426
|
artikel
|
| 7 |
Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes
|
Medford, Arielle J.
|
|
|
212 |
3 |
p. 437-447
|
artikel
|
| 8 |
Insurer and patient costs for repeat breast surgery after initial lumpectomy for breast cancer
|
Wing, Sam E.
|
|
|
212 |
3 |
p. 457-465
|
artikel
|
| 9 |
Local treatment of ipsilateral breast cancer recurrence: a sensitive decision-making process
|
Hannoun-Levi, Jean-Michel
|
|
|
212 |
3 |
p. 577-578
|
artikel
|
| 10 |
Mammographic calcifications association with risk of advanced breast cancer
|
Kerlikowske, Karla
|
|
|
212 |
3 |
p. 555-567
|
artikel
|
| 11 |
National trends in neoadjuvant systemic therapy utilization in patients with early-stage HER2-positive breast cancer from 2016–2021: The impact of the KATHERINE trial
|
Cohen, Lauren N.
|
|
|
212 |
3 |
p. 531-543
|
artikel
|
| 12 |
Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: a systematic review and meta-analysis
|
Liutti, Vitor Teixeira
|
|
|
212 |
3 |
p. 427-434
|
artikel
|
| 13 |
PD-L1 22C3 CPS in paired primary breast cancer and lung metastasis
|
Shin, Eunah
|
|
|
212 |
3 |
p. 569-576
|
artikel
|
| 14 |
Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers
|
Phadke, Sneha
|
|
|
212 |
3 |
p. 521-530
|
artikel
|
| 15 |
Promoting resilience in stress management (PRISM) for patients with early stage breast cancer: a pilot feasibility study
|
Rocque, Gabrielle B
|
|
|
212 |
3 |
p. 487-497
|
artikel
|
| 16 |
Severe hyponatremia with abemaciclib use in the absence of pre-existing renal disease
|
Kim, Tae Hoon
|
|
|
212 |
3 |
p. 435-436
|
artikel
|
| 17 |
Tumoral pSMAD2 as a prognostic biomarker in early-stage breast cancer: insights from the randomized SweBCG91RT trial
|
Stenmark Tullberg, Axel
|
|
|
212 |
3 |
p. 499-509
|
artikel
|
| 18 |
Utility of plasma circulating DNA tumor fraction in bone-only metastatic breast cancer: a real-world outcomes study
|
Bader, Gilbert
|
|
|
212 |
3 |
p. 475-486
|
artikel
|
Tijdschrift beschrijving